Neoadjuvant Chemoradiation Therapy Using Concurrent S-1 and Irinotecan in Rectal Cancer: Impact on Long-Term Clinical Outcomes and Prognostic Factors


      To assess the long-term outcomes of patients with rectal cancer who received neoadjuvant chemoradiation therapy (NCRT) with concurrent S-1 and irinotecan (S-1/irinotecan) therapy.

      Methods and Materials

      The study group consisted of 115 patients with clinical stage T3 or T4 rectal cancer. Patients received pelvic radiation therapy (45 Gy) plus concurrent oral S-1/irinotecan. The median follow-up was 60 months.


      Grade 3 adverse effects occurred in 7 patients (6%), and the completion rate of NCRT was 87%. All 115 patients (100%) were able to undergo R0 surgical resection. Twenty-eight patients (24%) had a pathological complete response (ypCR). At 60 months, the local recurrence-free survival was 93%, disease-free survival (DFS) was 79%, and overall survival (OS) was 80%. On multivariate analysis with a proportional hazards model, ypN2 was the only independent prognostic factor for DFS (P=.0019) and OS (P=.0064) in the study group as a whole. Multivariate analysis was additionally performed for the subgroup of 106 patients with ypN0/1 disease, who had a DFS rate of 85.3%. Both ypT (P=.0065) and tumor location (P=.003) were independent predictors of DFS. A combination of these factors was very strongly related to high risk of recurrence (P<.0001), which occurred most commonly in the lung.


      NCRT with concurrent S-1/irinotecan produced high response rates and excellent long-term survival, with acceptable adverse effects in patients with rectal cancer. ypN2 is a strong predictor of dismal outcomes, and a combination of ypT and tumor location can identify high-risk patients among those with ypN0/1 disease.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • MacFarlane J.K.
        • Ryall R.D.
        • Heald R.J.
        Mesorectal excision for rectal cancer.
        Lancet. 1993; 341: 457-460
        • Cooper S.G.
        • Bonaventura A.
        • Ackland S.P.
        • et al.
        Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: A phase II study.
        Clin Oncol (R Coll Radiol). 1993; 5: 169-173
        • Sauer R.
        • Liersch T.
        • Merkel S.
        • et al.
        Preoperative versus postoperative chemoradiation therapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
        J Clin Oncol. 2012; 30: 1926-1933
        • Minsky B.D.
        • Conti J.A.
        • Huang Y.
        • et al.
        Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer.
        J Clin Oncol. 1995; 13: 1409-1416
        • Minsky B.D.
        • Kemeny N.
        • Cohen A.M.
        • et al.
        Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer.
        Cancer. 1991; 67: 2859-2866
        • Chan A.
        • Wong A.
        • Langevin J.
        • Khoo R.
        Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma.
        Int J Radiat Oncol Biol Phys. 1993; 25: 791-799
        • Chan A.K.
        • Wong A.
        • Jenken D.
        • et al.
        Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 61: 665-677
        • Mehta V.K.
        • Cho C.
        • Ford J.M.
        • et al.
        Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
        Int J Radiat Oncol Biol Phys. 2003; 55: 132-137
        • Rosenthal D.I.
        • Haller D.G.
        • Landry J.C.
        • et al.
        Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
        Int J Radiat Oncol Biol Phys. 2008; 72: 108-113
        • Rödel C.
        • Liersch T.
        • Becker H.
        • et al.
        Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
        Lancet Oncol. 2012; 13: 679-687
        • Hoff P.M.
        • Janjan N.
        • Saad E.D.
        • et al.
        Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer.
        J Clin Oncol. 2000; 18: 3529-3534
        • De Paoli A.
        • Luppi G.
        • Friso M.L.
        • et al.
        Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: A multicentric phase II study.
        Ann Oncol. 2006; 17: 246-251
        • Klautke G.
        • Foitzik T.
        • Ludwig K.
        • et al.
        Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: Results from a phase I/II study.
        Br J Cancer. 2006; 94: 976-981
        • Koeberle D.
        • von Moos R.
        • Winterhalder R.
        • et al.
        Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
        Br J Cancer. 2008; 98: 1204-1209
        • Sato T.
        • Koizumi W.
        • Hayakawa K.
        • Okayasu I.
        • Watanabe M.
        Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1442-1447
        • Sato T.
        • Hatate K.
        • Onosato W.
        • et al.
        A phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: Clinical feasibility and response rate.
        Int J Radiat Oncol Biol Phys. 2011; 79: 677-683
        • Glynne-Jones R.
        • Pearce T.
        • Buyse M.
        Alternative clinical end points in rectal cancer—are we getting closer?.
        Ann Oncol. 2006; 17: 1239-1248
        • Nakata E.
        • Takai Y.
        • Nemoto K.
        • et al.
        S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
        Oncol Rep. 2006; 16: 465-471
        • Guichard S.
        • Bugat R.
        • Canal P.
        Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
        Biochem Pharmacol. 1998; 55: 667-676
        • Yamada Y.
        • Hamaguchi T.
        • Goto M.
        • et al.
        Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
        Br J Cancer. 2003; 89: 816-820
        • Sato T.
        • Ikeda A.
        • Yamanashi T.
        • et al.
        Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
        Expert Opin Pharmacother. 2008; 9: 1223-1228
        • Roh M.S.
        • O'Connell M.J.
        • Yothers G.
        • et al.
        Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
        J Clin Oncol. 2009; 27: 5124-5130
        • Gollins S.
        • Sun Myint A.
        • Haylock B.
        • et al.
        Preoperative chemoradiotherapy using concurrent capecitabine, and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: Impact on long-term clinical outcomes.
        J Clin Oncol. 2011; 29: 1042-1049
        • Das P.
        • Lin E.H.
        • Bhatia S.
        • et al.
        Preoperative chemoradiation with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer; a matched-pair analysis.
        Int J Radiat Oncol Biol Phys. 2006; 66: 1378-1383
        • Gerard J.P.
        • Azria D.
        • Gourgou-Bourgade S.
        • et al.
        Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial Accord 12/0405-Prodige2.
        J Clin Oncol. 2010; 28: 1638-1644
        • Rödel C.
        • Martus P.
        • Papadoupolos T.
        • et al.
        Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
        J Clin Oncol. 2005; 23: 8688-8696
        • Kim T.H.
        • Kim D.Y.
        • Jung K.H.
        • et al.
        Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
        Int J Radiat Oncol Biol Phys. 2010; 77: 1158-1165
        • Yeo S.G.
        • Kim T.H.
        • Chang H.J.
        • et al.
        Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).
        Ann Surg. 2010; 252: 998-1004
        • Katoh H.
        • Kokuba Y.
        • Satoh T.
        • et al.
        Diminishing impact of preoperative carcinoembryonic antigen (CEA) in prognosis of Dukes' C colorectal cancer.
        Anticancer Res. 2008; 28: 1933-1941
        • Katoh H.
        • Sato T.
        • Ozawa H.
        • et al.
        Prognostic significance of peritoneal tumour cells identified at surgery for colorectal cancer.
        Br J Surg. 2009; 96: 769-777
        • Katoh H.
        • Wang G.
        • Sato T.
        • et al.
        Anastomotic leakage contributes to the risk for systemic recurrence in stage II colorectal cancer.
        J Gastrointest Surg. 2011; 15: 120-129
        • Katoh H.
        • Wang G.
        • Sato T.
        • et al.
        Prognostic significance of preoperative bowel obstruction in stage III colorectal cancer.
        Ann Surg Oncol. 2011; 18: 2432-2441
        • Moeller B.J.
        • Li C.Y.
        • Dewhirst M.W.
        Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules.
        Cancer Cell. 2004; 5: 429-441
        • Yang M.H.
        • Chiou S.H.
        • Chen P.M.
        • et al.
        Direct regulation of TWIST by HIF-1alpha promotes metastasis.
        Nat Cell Biol. 2008; 10: 295-305
        • Dewhirst M.W.
        • Moeller B.
        Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.
        Nat Rev Cancer. 2008; 8: 425-437
        • Harada H.
        • Itasaka S.
        • Hirota K.
        • et al.
        Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.
        Nat Commun. 2012; 3: 783


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.